Publication date: May 17, 2019
Drug screening-i.e., testing the effects of a number of drugs in multiple cell lines-is used for drug discovery and development, and can also be performed to evaluate the heterogeneity of a disease entity. Notably, intertumoral heterogeneity is a large hurdle to overcome for establishing standard cancer treatment, necessitating disease models better than conventional established 2D cell lines for screening novel treatment candidates. In the present review, we outline recent progress regarding experimental cancer models having more physiological and clinical relevance for drug screening, which are important for the successful evaluation of cellular response to drugs. The review is particularly focused on drug screening using the cancer organoid model, which is emerging as a better physiological disease model than conventional established 2D cell lines. We also review the use of cancer organoids to examine intertumor and intratumor heterogeneity, and introduce the perspective of the clinical use of cancer organoids to enable precision medicine.
Kondo, J. and Inoue, M. Application of Cancer Organoid Model for Drug Screening and Personalized Therapy. 04643. 2019 Cells (8):5.
|Drug Development||Drug Screening|
|Precision Medicine||Precision medicine|
|Branches of biology|
- An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.
- Integrated cancer tissue engineering models for precision medicine.
- Organoid technology in cancer precision medicine.